Plus   Neg

FDA Panel Backs Pfizer's Xeljanz For Ulcerative Colitis

Pfizer Inc. (PFE) Thursday announced a favorable outcome of U.S. Food and Drug Administration Gastrointestinal Drugs Advisory Committee meeting on Pfizer's supplemental New Drug Application for Xeljanz (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis.

"Today's discussion underscored the significant unmet need that exists for people living with ulcerative colitis, a disease that is often debilitating and difficult to control. We are encouraged about the positive outcome of today's GIDAC meeting," said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

"If approved, tofacitinib will be the first Janus kinase inhibitor and the first oral therapy for adults living with moderately to severely active ulcerative colitis. We look forward to working with the FDA as it completes the review of our pending application."

The role of the GIDAC is to provide recommendations to the FDA; however, the recommendations are not binding. FDA's decision on whether or not to approve tofacitinib for UC is expected by the Prescription Drug User Fee Act date in June 2018.

Ulcerative Colitis is a chronic and often debilitating inflammatory bowel disease that affects millions of people worldwide. Symptoms include chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Delta Airlines becomes the latest airline to experience pet transport disaster. An 8-week-old puppy was flown across the country to the wrong airports by Delta Airlines landing in Detroit, Las Vegas and Salt Lake City before finally making to Idaho. On Saturday, a breeder put Josh Schlaich's new,... Facebook stock is plunging due to self-inflicted wounds. What was once America's favorite social media site is being a accused of turning into a cesspool of misinformation and narcissism. Facebook Inc.'s security chief, Alex Stamos, plans to step down from the company amid questions over Russia's... Media company Tronc, Inc. said Monday that Michael Ferro has stepped down as chairman of its board of directors. The company named Chief Executive Justin Dearborn as chairman of the board. Tronc noted that Ferro, its largest shareholder, is retiring from the board as the company prepares to close on the $500 million sale of its flagship newspaper, the Los Angeles Times, to local ownership.
comments powered by Disqus
Follow RTT